(VIANEWS) – Today, the Innrs artificial intelligence algorithm suggests a high probability of discovering the approximate price for tomorrow of Merck MRK, Eli Lilly and Company LLY and others.
Via News will regularly fact-check this AI algorithm that aims to consistently predict the next session price and next week’s trend of financial assets.
Innrs provides A.I.-based statistical tools to help investors make decisions. The table below shows the financial assets predicting price, ordered by the highest expected accuracy.
Innrs officials say this tool helps investors make better-informed decisions, supposedly used alongside other relevant financial information and the specific trader strategy.
In the next session, Via News will report the finding on the algorithm precision.
| Financial Asset | Accuracy | Close Price | Prediction |
|---|---|---|---|
| Merck (MRK) | 98.27% | $109.78 | ⇧ $112.48 |
| Eli Lilly and Company (LLY) | 94.35% | $369.4 | ⇧ $377.09 |
| Astrazeneca (AZN) | 94.05% | $68.44 | ⇧ $70.14 |
| Coca-Cola (KO) | 93.7% | $63.51 | ⇧ $64.87 |
| Genmab (GMAB) | 93.62% | $46.01 | ⇧ $46.56 |
| Booking Holdings (BKNG) | 93.5% | $2053.03 | ⇧ $2068.68 |
| Five9 (FIVN) | 93.41% | $66.13 | ⇧ $68.73 |
| Johnson & Johnson (JNJ) | 93.33% | $178.97 | ⇧ $182.64 |
| Church & Dwight Company (CHD) | 93.23% | $80.38 | ⇧ $83.25 |
| Bristol (BMY) | 92.98% | $80.86 | ⇧ $82.68 |
| Wausau Pape (WPP) | 89.36% | $52.4 | ⇧ $52.8 |
| TJX Companies (TJX) | 89.34% | $79.43 | ⇧ $81.71 |
| Boston Scientific (BSX) | 89.23% | $45.44 | ⇧ $45.89 |
| Regeneron Pharmaceuticals (REGN) | 89.15% | $755.73 | ⇧ $776.06 |
| Smith & Nephew (SNN) | 89.13% | $26.8 | ⇧ $26.89 |
| Royal Caribbean Cruises (RCL) | 88.84% | $59.39 | ⇧ $60.16 |
| Internationa Flavors & Fragrances (IFF) | 88.73% | $106.85 | ⇧ $110.29 |
| Laboratory Corporation of America Holdings (LH) | 88.7% | $236.79 | ⇧ $244.38 |
| Ross Stores (ROST) | 88.62% | $117.21 | ⇧ $121.95 |
| Amicus Therapeutics (FOLD) | 88.62% | $12.34 | ⇧ $12.4 |
| VALE (VALE) | 88.62% | $16.43 | ⇧ $16.72 |
| Gilead Sciences (GILD) | 88.6% | $87.89 | ⇧ $89.14 |
| Live Nation Entertainment (LYV) | 88.57% | $73.75 | ⇧ $75.11 |
| Ares Capital (ARCC) | 88.51% | $19.21 | ⇧ $19.66 |
| Exelon (EXC) | 88.38% | $41.75 | ⇧ $42.8 |
| NextEra Energy (NEE) | 88.37% | $85.23 | ⇧ $87.14 |
| Public Service Enterprise Group (PEG) | 88.26% | $60.28 | ⇧ $61.77 |
| Stryker Corp (SYK) | 88.24% | $238.09 | ⇧ $243.23 |
| Celanese (CE) | 88.17% | $108.49 | ⇧ $109.67 |
| Zoom (ZM) | 87.99% | $72.69 | ⇧ $73.55 |
| White Mountains Insurance Group (WTM) | 87.97% | $1303.87 | ⇧ $1343.41 |
1. Merck (MRK)
Shares of Merck jumped 9.74% in from $100.04 to $109.78 at 18:21 EST on Monday, following the last session’s upward trend. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Yearly Top and Bottom Value
Merck’s stock is valued at $109.78 at 18:21 EST, under its 52-week high of $110.98 and way higher than its 52-week low of $71.50.
More news about Merck.
2. Eli Lilly and Company (LLY)
Shares of Eli Lilly and Company rose 1.16% in from $365.16 to $369.40 at 18:21 EST on Monday, following the last session’s upward trend. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Eli Lilly and Company develops and markets pharmaceuticals for human use worldwide. Basaglar is available, as well as Humalog Mix 75/25 and Humalog U100. Humalog U200 and Humalog Mix 50/50. It also offers insulin lispro and insulin lisproprotamine. Insulin lispro mix 75/25 and Humulin 70/30. Humulin N and Humulin R are both diabetes medications. Trulicity, Jardiance and Trajenta are type 2 diabetic products. Alimta is available for the treatment of non-small-cell lung cancer. Olumiant is available for rheumatoid arthritis; Taltz can be used for plaque psoriasis and psoriatic arthritis. Cymbalta is available for depression, diabetes peripheral neuropathic, anxiety disorder and fibromyalgia; Emgality can prevent migraines and treat episodic cluster headaches; Zyprexa is for schizophrenia and bipolar I disorder; as well as bipolar maintenance. Bamlanivimab is available for COVID-19, as well as etesevimab and Bebtelovimab. Cialis can be used for benign prostatic hyperplasia and erectile dysfunction. Forteo treats osteoporosis. It has developed collaborations with Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc.
Sales Growth
Eli Lilly and Company’s sales growth is 15.2% for the present quarter and 2.8% for the next.
Growth Estimates Quarters
For the current quarter, the company expects to grow 13.5% while for the next it will drop 6.7%.
Annual Top and Bottom Value
Eli Lilly and Company stock was valued at $369.40 as of 18:21 EST. This is lower than the 52-week high at $375.19 and much higher than the 52-week low at $231.87.
More news about Eli Lilly and Company.
3. Astrazeneca (AZN)
Shares of Astrazeneca rose by a staggering 12.12% in from $61.04 to $68.44 at 18:21 EST on Monday, after three sequential sessions in a row of gains. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
AstraZeneca PLC is a biopharmaceutical firm that focuses on developing, manufacturing and marketing prescription drugs. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Synagis is a respiratory syncytialvirus treatment; Fluenz Tetra/FluMist quadrivalent for Influenza; Serocort IR/Seroquel XR to treat schizophrenia bipolar disorder; Nexium and Losec/Prilosec are gastroenterology treatments; Vaxzevria, Soliris and Strensiq are covid-19 medications. Through distributors and representative offices located in Europe, Americas, Asia and Africa, the company provides primary and specialty care doctors with services. The company has a partnership agreement with Regeneron Pharmaceuticals, Inc. for research, development, and marketing small molecule medications for obesity. Neurimmune AG will develop and market NI006 and Ionis Pharmaceuticals, Inc. for eplontersen, a liver targeted antisense treatment in Phase III for treatment of transthyretin. Proteros Biostructures GmbH and Sierra Oncology, Inc. will jointly develop and commercialize AZD5153. AstraZeneca PLC was previously known as Zeneca Group PLC. AstraZeneca Plc was founded in 1992. It is located in Cambridge, United Kingdom.
Moving Average
Astrazeneca’s market value is much higher than its 50-day average moving price of $59.47, and it is also significantly more than its 200-day average moving price of $63.16.
Classification of Stock Prices
The stochastic oscillator is a helpful indicator for overbought or oversold situations.
Stock of Astrazeneca is oversold (=20).
Growth Estimates Quarters
For the current quarter, the company expects to grow by 33.3% while it will drop by 15.5% in the next.
Sales Growth
Astrazeneca sales growth was 10.5% in the current quarter, and 5.2% the following.
More news about Astrazeneca.
4. Coca-Cola (KO)
Shares of Coca-Cola jumped 6.79% in from $59.47 to $63.51 at 18:21 EST on Monday, after three successive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Coca-Cola Company is a global beverage manufacturer, marketer, and seller of non-alcoholic beverages. It offers sparkling soft drinks, flavored water and enhanced water; juice, milk and plant-based drinks; tea and coffee; as well as energy drinks. The company also sells beverage concentrates or syrups as well as fountain syrups for fountain retailers such as convenience shops and restaurants. It sells products under Coca-Cola/Diet Coke/Coca-Cola Light and Coca-Cola Zero Sugar brands. The company operates via a network that includes independent bottling partners and distributors as well as wholesalers and bottling operators. It was established in Atlanta, Georgia in 1886.
Yearly Top and Bottom Value
Coca-Cola’s stock is valued at $63.51 at 18:24 EST, under its 52-week high of $67.20 and way higher than its 52-week low of $54.02.
Moving Average
Coca-Cola’s value is above its 50-day moving average of $58.77 and higher than its 200-day moving average of $61.66.
Sales Growth
Coca-Cola saw sales growth of 4.8% in the current quarter, and 6.3% the following quarter.
Revenue growth
The year-over-year revenue growth was 10.2%. 42.34B has been reported for the 12 trailing months.
More news about Coca-Cola.
5. Genmab (GMAB)
Shares of Genmab jumped by a staggering 15.89% in from $39.7 to $46.01 at 18:21 EST on Monday, following the last session’s upward trend. NASDAQ is falling 1.93% to $11,239.94, following the last session’s downward trend.
Genmab A/S is a Danish company that develops and markets antibody therapies for cancer treatment. DARZALEX is a monoclonal human antibody that can be used to treat multiple myeloma. Teprotumumab can also be used for treatment of the thyroid eye disorder. Amivantamab and Amivantamab are available for advanced, metastatic, or esophageal, cancers and NSCLC. Daratumumab is used to treat MM and non-MM blood tumors and AL Amyloidosis. The company also produces products. Phase 2 includes Teclistamab to treat vaso-occlusive crisis; Camidanlumab tesirine for treatment of hodgkin lymphoma; JNJ-64407564 for treating MM; PRV-015 to treat celiac; Mim8 to treat haemophilia; and Lu AF82422 to treat multiple system atrophy. It also has 20 preclinical trials. Seagen Inc. has granted the company a collaboration and commercial license to develop tisotumab. The company also has a partnership agreement with CureVac AG to research and develop differentiated mRNA-based antibodies products. AbbVie is responsible for developing epcoritamab. There are collaborations with BioNTech, Janssen, Novo Nordisk A/S, Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999. Its headquarters is in Copenhagen, Denmark.
Revenue growth
The year-on-year revenue growth was 60.3%. It now stands at 10.21B in the 12 trailing months.
Sales Growth
Genmab’s sales growth is 26.8% for the present quarter and 31.8% for the next.
More news about Genmab.
6. Booking Holdings (BKNG)
Shares of Booking Holdings jumped by a staggering 11.55% in from $1840.46 to $2,053.03 at 18:21 EST on Monday, following the last session’s upward trend. NASDAQ is falling 1.93% to $11,239.94, following the last session’s downward trend.
Booking Holdings Inc. offers online reservations for travel and restaurants worldwide. Booking.com offers accommodation bookings online; Rentalcars.com provides rental car services online; Priceline which allows customers to make travel reservations online for hotel, flight and rental cars. Agoda, which offers online accommodations reservation, flight, ground transport, and activity reservation services, is also available. KAYAK is an online price comparison site that lets consumers search for and compare prices on travel itineraries. This includes information about rental cars, airline tickets, hotel reservations, and accommodation. OpenTable allows customers to book online restaurants. It also offers insurance and management services for consumers and travel service providers. The original name of the company was The Priceline Group Inc., but it changed its name in February 2018 to Booking Holdings Inc. It was established in 1997. The headquarters are located in Norwalk in Connecticut.
Volatility
Booking Holdings’s intraday variation average for the week and quarter ended last week at 1.25%, 0.577% and 1.98%, respectively.
Booking Holdings had the highest average volatility amplitudes of 1.72%, 1.61% and 1.98% in the last quarter.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 32.3% and 48.3%, respectively.
More news about Booking Holdings.
7. Five9 (FIVN)
Shares of Five9 rose by a staggering 40.7% in from $47 to $66.13 at 18:21 EST on Monday, after three sequential sessions in a row of gains. NASDAQ is sliding 1.93% to $11,239.94, following the last session’s downward trend.
Five9, Inc. and its subsidiaries provide cloud software for call centers across the United States. It offers a virtual contact center platform, which includes a range of apps that allow for a wide variety of customer service and sales functions. The company’s platform allows clients to handle customer interactions via voice, video chat, email and social media. It also offers click-to call, callback and mobile channel management. Customers can find the company in a variety of industries, including banking, financial services, outsourcing, education, health care, technology and consumer. Five9, Inc., was founded in 2001. It is located in San Ramon, California.
Moving Average
Five9 is worth more than its $50 moving average $62.50, and much less than its $200 moving average $91.24.
Sales Growth
The sales growth of Five9 is 17.8% in the current quarter, and 14.5% the following.
Yearly Top and Bottom Value
Five9’s stock is valued at $66.13 at 18:25 EST, way under its 52-week high of $144.63 and way higher than its 52-week low of $46.61.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 2.4% and 13.6% respectively.
More news about Five9.
8. Johnson & Johnson (JNJ)
Shares of Johnson & Johnson jumped 3.46% in from $172.98 to $178.97 at 18:21 EST on Monday, after three consecutive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Sales Growth
Johnson & Johnson’s sales growth is negative 3.6% for the ongoing quarter and 0.7% for the next.
Moving Average
Johnson & Johnson’s worth is higher than its 50-day moving average of $170.06 and above its 200-day moving average of $172.55.
Classification of Stock Prices
The stochastic oscillator is a helpful indicator for overbought or oversold situations.
Johnson & Johnson stock is oversold (=20).
More news about Johnson & Johnson.
9. Church & Dwight Company (CHD)
Shares of Church & Dwight Company rose by a staggering 10.22% in from $72.93 to $80.38 at 18:21 EST on Monday, after five successive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
Volatility
The Church & Dwight Company last week’s and last month’s intraday variations averages were 1.48%, 0.82% and 1.16%, respectively.
Church & Dwight Company had the highest amplitude average volatility of any company: 1.48% (last Wednesday), 0.99%(last month) and 1.16% [last quarter].
More news about Church & Dwight Company.
10. Bristol (BMY)
Shares of Bristol jumped 2.02% in from $79.26 to $80.86 at 18:21 EST on Monday, after five sequential sessions in a row of gains. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Moving Average
Bristol’s worth is way above its 50-day moving average of $71.43 and way higher than its 200-day moving average of $72.59.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 7.5% and a negative 3.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.6%, now sitting on 47.14B for the twelve trailing months.
More news about Bristol.
11. Wausau Pape (WPP)
Shares of Wausau Pape jumped by a staggering 13.1% in from $46.33 to $52.40 at 18:21 EST on Monday, after five successive sessions in a row of gains. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
WPP plc, a creative transformation company, provides communications, experience, commerce, and technology services in North America, the United Kingdom, Western Continental Europe, the Asia Pacific, Latin America, Africa, the Middle East, and Central and Eastern Europe. The company operates through three segments: Global Integrated Agencies, Public Relations, and Specialist Agencies. It offers plans and creates marketing and branding campaigns; designs and produces advertisements across various media; and provides media buying services, such as strategy and business development, media investment, data and technology, and content. The company also offers public relations advisory services to clients who are seeking to communicate with a range of stakeholders from consumers to governments and the business and financial communities; and specialist agency services. WPP plc was founded in 1985 and is based in London, the United Kingdom.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.9%, now sitting on 12.8B for the twelve trailing months.
Volatility
Wausau Pape’s last week, last month’s, and last quarter’s current intraday variation average was 0.84%, 0.84%, and 1.79%.
Wausau Pape’s highest amplitude of average volatility was 0.84% (last week), 1.46% (last month), and 1.79% (last quarter).
More news about Wausau Pape.
12. TJX Companies (TJX)
Shares of TJX Companies rose by a staggering 10.11% in from $72.14 to $79.43 at 18:21 EST on Monday, after two consecutive sessions in a row of gains. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
The TJX Companies, Inc., together with its subsidiaries, operates as an off-price apparel and home fashions retailer. It operates through four segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The company sells family apparel, including footwear and accessories; home fashions, such as home basics, furniture, rugs, lighting products, giftware, soft home products, decorative accessories, tabletop, and cookware, as well as expanded pet, kids, and gourmet food departments; jewelry and accessories; and other merchandise. As of February 23, 2022, it operated 1,284 T.J. Maxx, 1,148 Marshalls, 850 HomeGoods, 59 Sierra, and 39 Homesense stores, as well as tjmaxx.com, marshalls.com, and sierra.com in the United States; 293 Winners, 147 HomeSense, and 106 Marshalls stores in Canada; 618 T.K. Maxx and 77 Homesense stores, as well as tkmaxx.com in Europe; and 68 T.K. Maxx stores in Australia. The company was incorporated in 1962 and is headquartered in Framingham, Massachusetts.
More news about TJX Companies.
13. Boston Scientific (BSX)
Shares of Boston Scientific rose 8.4% in from $41.92 to $45.44 at 18:21 EST on Monday, after four successive sessions in a row of gains. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Boston Scientific Corporation designs, produces, and markets medical products for various medical specialty areas. The company operates in three distinct segments, MedSurg (Rhythm and Neuro), Cardiovascular, and Cardiovascular. It offers products to diagnose and treat digestive and pulmonary problems; various urological, pelvic and other conditions; an implantable cardioverter; implantable cardiac defibrillators; pacemakers; and an implantable cardiac rhythmization therapy pacemaker; as well as remote patient management software. The company also offers medical technology to treat rhythm and rate disorders in the heart. This includes 3-D cardiac mapping, navigation solutions, ablation, diagnostic catheters and mapping catheters. Delivery sheaths and other accessories. It also sells spinal cord stimulator systems that manage chronic pain. Indirect decompression systems and deep brain stimulation. The company also offers interventions in cardiology, such as drug-eluting cardiac stents for the treatment of coronary heart disease, percutaneous coronary intervention products for the treatment atherosclerosis, intravascular catheter directed ultrasound imaging catheters and fractional flow reserve devices. It also provides structural heart therapies. It also offers stents and balloon catheters as well as wires and atherectomy system to treat arterial disease. Marlborough is the headquarters of this company, which was founded in 1979.
Yearly Top and Bottom Value
Boston Scientific’s stock is valued at $45.44 at 18:26 EST, below its 52-week high of $47.50 and way above its 52-week low of $34.98.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 12.57B for the twelve trailing months.
Volatility
The intraday variation average for Boston Scientific in the last week, last year, and quarter was 1.57%, 0.622%, and 1.28 respectively.
Boston Scientific had the highest average volatility amplitudes of 1.57%, 1.30% and 1.28% respectively in last week and quarter.
More news about Boston Scientific.
14. Regeneron Pharmaceuticals (REGN)
Shares of Regeneron Pharmaceuticals rose 0.72% in from $750.33 to $755.73 at 18:21 EST on Monday, after three consecutive sessions in a row of gains. NASDAQ is sliding 1.93% to $11,239.94, following the last session’s downward trend.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Volatility
Regeneron Pharmaceuticals’s intraday variation average for the week and quarter ended December 31, 2013, 0.12% and 1.69 respectively.
Regeneron Pharmaceuticals had the highest average volatility amplitudes of 1.20%, 1.00% and 1.69% in the last week.
Classification of Stock Prices
The stochastic oscillator is a helpful indicator for overbought or oversold situations.
The stock of Regeneron Pharmaceuticals is oversold (=20).
Annual Top and Bottom Value
Regeneron Pharmaceuticals’ stock was valued at 755.73 at 18.26 EST. This is lower than the 52-week high $769.63, and much higher than its 52 week low of $538.03.
More news about Regeneron Pharmaceuticals.
15. Smith & Nephew (SNN)
Shares of Smith & Nephew jumped by a staggering 10.56% in from $24.24 to $26.80 at 18:21 EST on Monday, after five sequential sessions in a row of gains. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
Smith & Nephew plc and its subsidiaries develop, market, sell, and distribute medical devices around the world. It offers products to replace knees, hip implants that can be used for reconstruction of the hip joint; as well as trauma and extremities products. These include both internal and external devices for stabilizing severe fractures or correcting deformities. The company also offers products and technologies for sports medicine, which include instruments and devices that allow surgeons to repair the joint, like soft tissue injuries, degenerative conditions, or the replacement of the hip, knee, or shoulder. It also sells meniscal repair and technology systems. The company also offers fluid management equipment, high-definition cameras and digital image capture. It can provide monitors for visualization of the joint, as well as radio frequency, electronic and mechanical tissue resection tools. Hand instruments are available to remove damaged tissue. It also offers advanced wound care products to treat and prevent chronic and acute wounds. These include leg, diabetes, pressure, burns, post-operative wounds, and wounds that result from surgery. The company mainly serves healthcare professionals. Smith & Nephew plc, which was established in 1856, is based in Watford in the United Kingdom.
Annual Top and Bottom Value
Smith & Nephew stock was valued at $26.80 as of 18:26 EST. This is way lower than its 52 week high of $37.05 but higher than its 52 week low of $21.78.
Volatility
Smith & Nephew last week’s and last month’s intraday variations averages were 1.09%, 0.49% and 1.55%, respectively.
Smith & Nephew had the highest amplitude average volatility, at 1.09% last week, 1.34% last month and 1.55% in quarter.
Moving Average
Smith & Nephew is worth more than its moving average for 50 days of $23.72 (and below its moving average for 200 days of $28.89).
More news about Smith & Nephew.
16. Royal Caribbean Cruises (RCL)
Shares of Royal Caribbean Cruises jumped by a staggering 14.1% in from $52.05 to $59.39 at 18:21 EST on Monday, after two successive sessions in a row of losses. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
Royal Caribbean Cruises Ltd. operates as a cruise company worldwide. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, Azamara, and Silversea Cruises brands, which comprise a range of itineraries that call on approximately 1,000 destinations. As of February 25, 2022, it operated 61 ships. The company was founded in 1968 and is headquartered in Miami, Florida.
Yearly Top and Bottom Value
Royal Caribbean Cruises’s stock is valued at $59.39 at 18:27 EST, way below its 52-week high of $98.27 and way higher than its 52-week low of $31.09.
More news about Royal Caribbean Cruises.
17. Internationa Flavors & Fragrances (IFF)
Shares of Internationa Flavors & Fragrances jumped by a staggering 11.17% in from $96.11 to $106.85 at 18:21 EST on Monday, after four sequential sessions in a row of gains. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through Nourish, Scent, Health & Biosciences, and Pharma Solutions segments. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds, and savory solutions and inclusions. It also provides natural food protection ingredients consist of natural antioxidants and anti-microbials as well as beverages, sweets , and dairy products. The Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, botanicals, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients. The Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.
Sales Growth
Internationa Flavors & Fragrances’s sales growth for the next quarter is 8.3%.
More news about Internationa Flavors & Fragrances.
18. Laboratory Corporation of America Holdings (LH)
Shares of Laboratory Corporation of America Holdings jumped 1.29% in from $233.77 to $236.79 at 18:21 EST on Monday, after two sequential sessions in a row of losses. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Laboratory Corporation of America Holdings is a worldwide life science company. It provides crucial information that helps doctors, nurses, pharmacist companies, researchers and patients to make informed decisions. Labcorp Diagnostics is (Dx), and Labcorp Drug Development(DD) are its two main segments. There are many tests it offers, including blood chemistry, blood cell counts and urinalysis, blood cell counts and thyroid testing. It also provides tests such as PAP and hemoglobin tests. Labcorp Drug Development (DD) is its two-part segment. It also offers specialty testing, which includes gene-based or esoteric tests; advanced testing targets specific diseases such as anatomic pathology/oncology and cardiovascular disease. Online and mobile apps are available to patients for checking test results. There is also an online application that can be used by managed care and accountable organizations. The company offers complete drug, medical, and companion diagnostic solutions, from the early stages of research through clinical development and access to commercial markets. Managed care companies, pharmaceutical, biotechnology and medical device, diagnostics firms, government agencies, doctors and other healthcare providers as well as hospitals and health system employers, consumers, contractors research organisations and independent clinical labs, are all served. Laboratory Corporation of America Holdings and Tigerlily Foundation have a collaborative agreement to expand the number of women of color participating in clinical trials. This company was founded in 1994, and its headquarters are in Burlington (North Carolina).
Sales Growth
Laboratory Corporation of America Holdings saw a 4.3% increase in sales for the current quarter, and a negative 5.5% growth for the following.
Yearly Top and Bottom Value
Laboratory Corporation of America Holdings’s stock is valued at $236.79 at 18:27 EST, way below its 52-week high of $317.17 and way above its 52-week low of $200.32.
Moving Average
Laboratory Corporation of America Holdings is worth more than its 50-day average of $218.93, and less than its 200-day average of $2546.53.
More news about Laboratory Corporation of America Holdings.
19. Ross Stores (ROST)
Shares of Ross Stores rose by a staggering 26.03% in from $93 to $117.21 at 18:21 EST on Monday, after five sequential sessions in a row of gains. NASDAQ is dropping 1.93% to $11,239.94, following the last session’s downward trend.
Ross Stores, Inc., along with its affiliates, operate off-price home fashion and apparel stores under the Ross Dress for Less brand and dd’s DISCOUNTS brands. The company’s retail stores sell primarily apparel, accessories and footwear. Ross Dress for Less is a company store that sells its products in specialty and department stores. dd’s DISCOUNTS stores are for those with lower incomes and sell their products at discount and department stores. It had approximately 2000 stores operating in 40 US states and Guam under Ross Dress for Less or dd’s DISCOUNTS. Ross Stores, Inc. is an American company that was founded in 1957. Its headquarters are in Dublin, California.
More news about Ross Stores.
20. Amicus Therapeutics (FOLD)
Shares of Amicus Therapeutics jumped by a staggering 19.81% in from $10.3 to $12.34 at 18:21 EST on Monday, after three consecutive sessions in a row of gains. NASDAQ is dropping 1.93% to $11,239.94, following the last session’s downward trend.
Amicus Therapeutics, Inc. is a biotech company that focuses on the discovery, development, and delivery of medicines for rare conditions. Galafold is an oral precision medicine that treats adults who have been diagnosed with Fabry disease. It also has product candidates. This product includes a Galactosidase Alpha gene variant and Galafold. AT-GAA is a new treatment for Pompe disease. It also offers enzyme replacement therapies to Pompe diseases. CLN3 (which is currently in Phase 1/2 clinical trial) evaluates whether a single intrathecal injection of AAV serotype ATX-502 gene therapy can be safe and effective in treating CLN3. CDKL5 is a gene that encodes CDKL5 and regulates essential proteins in normal brain development. Collaboration and licensing agreements have been signed with Nationwide Children’s Hospital, University of Pennsylvania and GlaxoSmithKline. Amicus Therapeutics Inc. was established in 2002. It is located in Philadelphia, Pennsylvania.
More news about Amicus Therapeutics.
21. VALE (VALE)
Shares of VALE rose by a staggering 18.2% in from $13.9 to $16.43 at 18:21 EST on Monday, after five sequential sessions in a row of gains. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally. The company operates through Ferrous Minerals and Base Metals segments. The Ferrous Minerals segment produces and extracts iron ore and pellets, manganese, ferroalloys, and other ferrous products; and provides related logistic services. The Base Metals segment produces and extracts nickel and its by-products, such as gold, silver, cobalt, precious metals, and others, as well as copper. The company was formerly known as Companhia Vale do Rio Doce and changed its name to Vale S.A. in May 2009. Vale S.A. was founded in 1942 and is headquartered in Rio de Janeiro, Brazil.
More news about VALE.
22. Gilead Sciences (GILD)
Shares of Gilead Sciences jumped 7.89% in from $81.46 to $87.89 at 18:21 EST on Monday, after four sequential sessions in a row of gains. NASDAQ is falling 1.93% to $11,239.94, following the last session’s downward trend.
Gilead Sciences, Inc. is a biopharmaceutical firm that discovers, develops, commercializes and markets medicines in areas where there are unmet medical needs in America, Europe, and around the world. Biktarvy and Genvoya products are available. The company also sells Yescarta and Tecartus products, Trodelvy and Zydelig for cell therapy and hematology patients. The company also offers Letairis, an oral treatment for pulmonary arterial hypertension, Ranexa, an oral treatment for chronic angina, and AmBisome which is a liposomal treatment for serious invasive fungal infections. Gilead Sciences, Inc. is a member of the following collaborations: Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., Inc., Inc., Inc. It was founded in 1987, and has its headquarters in Foster City.
Moving Average
Gilead Sciences’s value is way higher than its 50-day moving average of $74.36 and way higher than its 200-day moving average of $65.06.
More news about Gilead Sciences.
23. Live Nation Entertainment (LYV)
Shares of Live Nation Entertainment jumped 0.71% in from $73.23 to $73.75 at 18:21 EST on Monday, after five successive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Live Nation Entertainment, Inc. operates as a live entertainment company. It operates through Concerts, Ticketing, and Sponsorship & Advertising segments. The Concerts segment promotes live music events in its owned or operated venues, and in rented third-party venues; operates and manages music venues; produces music festivals; creates associated content; and offers management and other services to artists. The Ticketing segment manages the ticketing operations, including the provision of ticketing software and services to clients for tickets and event information through its primary websites livenation.com and ticketmaster.com, as well as provides ticket resale services. This segment sells tickets for its events, as well as for third-party clients in various live event categories, such as arenas, stadiums, amphitheaters, music clubs, concert promoters, professional sports franchises and leagues, college sports teams, performing arts venues, museums, and theaters through websites, mobile apps, and ticket outlets. The Sponsorship & Advertising segment sells international, national, and local sponsorships and placement of advertising, including signage, promotional programs, rich media offering that comprise advertising related with live streaming and music-related content; and ads across its distribution network of venues, events, and websites. This segment also manages the development of strategic sponsorship programs, as well as develops, books, and produces custom events or programs for specific brands. As of December 31, 2021, it owned, operated, or leased 165 entertainment venues in North America and 94 entertainment venues internationally. The company was formerly known as Live Nation, Inc. and changed its name to Live Nation Entertainment, Inc. in January 2010. Live Nation Entertainment, Inc. was incorporated in 2005 and is headquartered in Beverly Hills, California.
Revenue Growth
Year-on-year quarterly revenue growth grew by 669.9%, now sitting on 11.64B for the twelve trailing months.
Classification of Stock Prices
The stochastic oscillator is a helpful indicator for overbought or oversold situations.
Live Nation Entertainment stock is oversold (=20).
Moving Average
Live Nation Entertainment’s worth is under its 50-day moving average of $75.52 and way below its 200-day moving average of $92.35.
Yearly Top and Bottom Value
Live Nation Entertainment’s stock is valued at $73.75 at 18:30 EST, way under its 52-week high of $126.79 and way above its 52-week low of $65.05.
More news about Live Nation Entertainment.
24. Ares Capital (ARCC)
Shares of Ares Capital dropped 2.76% in from $19.76 to $19.21 at 18:21 EST on Monday, after two successive sessions in a row of gains. NASDAQ is sliding 1.93% to $11,239.94, following the last session’s downward trend.
Ares Capital Corporation, a business development firm, specializes in the acquisition, recapitalization and mezzanine of middle-market companies. The company also provides growth capital and general financing. The fund prefers investments in businesses that are involved in basic and growth manufacturing as well as business services and consumer products. It also invests in health and care products and services. It will consider investing in technology, restaurants, and oil and gas sectors. The fund focuses its investments on the Northeast, Mid-Atlantic and Southwest regions. Its New York office is responsible for the Midwest, Midwest, Southeast, and Southwest regions. From the Los Angeles Office, it also handles the Western region. It typically invests $20 to $200 million, and up to $400 million in companies that have an EBITDA of $10 million or more. This fund makes debt investments of between $10 million to $100 million. It invests via revolvers and first lien loans. It also considers subordinated and senior debt financings from third parties. The fund may consider the purchase of distressed or discounted debt. It prefers to act as an agent for and/or direct the investments it makes. It also wants to be a board member in the portfolio companies.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 2.1% while it will drop by 13.8% in the following.
Revenue growth
The year-over-year revenue growth was 4.4%. It now stands at 1.89B in the 12 trailing months.
Moving Average
Ares Capital’s worth is below its 50-day moving average of $19.42 and under its 200-day moving average of $20.13.
More news about Ares Capital.
25. Exelon (EXC)
Shares of Exelon rose by a staggering 13.92% in from $36.65 to $41.75 at 18:21 EST on Monday, following the last session’s downward trend. NASDAQ is sliding 1.93% to $11,239.94, following the last session’s downward trend.
Exelon Corporation is a holding company for utility services. It engages in energy generation, distribution, and marketing in both the United States of America and Canada. The company owns a variety of facilities, including solar, nuclear, renewable, energy, biofuel, and hydroelectric. It also offers electricity wholesale to retail customers and natural gas and renewable energy as well as other energy-related products, services, and goods. It is also involved in the regulation and purchase of electricity and natural gases; transmission and distribution, as well distribution of natural gas retail customers. The company also offers support services such as legal, human resource, information technology and accounting. The company serves residential, commercial, industrial and governmental customers as well as distribution utilities and cooperatives. Exelon Corporation, which was founded in 1999, is located in Chicago.
Annual Top and Bottom Value
Exelon stock was valued at $41.75 as of 18:31 EST. This is way below its 52 week high of $50.71, and far above its 52 week low of $35.19.
More news about Exelon.
26. NextEra Energy (NEE)
Shares of NextEra Energy jumped by a staggering 10.17% in from $77.36 to $85.23 at 18:21 EST on Monday, after five sequential sessions in a row of gains. NYSE is falling 1.85% to $15,474.79, following the last session’s upward trend.
NextEra Energy, Inc., through its subsidiaries, generates, transmits, distributes, and sells electric power to retail and wholesale customers in North America. The company generates electricity through wind, solar, nuclear, coal, and natural gas facilities. It also develops, constructs, and operates long-term contracted assets that consists of clean energy solutions, such as renewable generation facilities, battery storage projects, and electric transmission facilities; sells energy commodities; and owns, develops, constructs, manages and operates electric generation facilities in wholesale energy markets. As of December 31, 2021, the company had approximately 28,564 megawatts of net generating capacity; approximately 77,000 circuit miles of transmission and distribution lines; and 696 substations. It serves approximately 11 million people through approximately 5.7 million customer accounts in the east and lower west coasts of Florida. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. The company was founded in 1925 and is headquartered in Juno Beach, Florida.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
NextEra Energy’s stock is considered to be oversold (<=20).
More news about NextEra Energy.
27. Public Service Enterprise Group (PEG)
Shares of Public Service Enterprise Group rose 5.37% in from $57.21 to $60.28 at 18:21 EST on Monday, after two successive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Public Service Enterprise Group Incorporated operates through its subsidiaries as an energy company, primarily in the Northeastern United States and Mid-Atlantic United States. The company operates in two segments: PSE&G Power and PSEG Power. PSE&G is a segment that transmits electricity, distributes electricity, gas, and invests in energy efficiency programs, solar generation, and other related projects. It also offers repair and service for appliances. It had an electric transmission and distribution network of 25,000 circuits and 56 switching stations. There were also five electric distribution headquarters. There are also five subheadquarters and four electric distribution headquarters. The electric distribution headquarters has a total of 12,353 megavolts. There are also 235 substations that have a capacity of 9,285 Megavolt Amperes. 18,000 miles of gas mains. 12 sub-headquarters and two gas distribution headquarters. One meter shop and 58 natural gas regulator and metering stations. Public Service Enterprise Group Incorporated, which was founded in 1985, is located in Newark.
Classification of Stock Prices
The stochastic oscillator is a helpful indicator for overbought or oversold situations.
Public Service Enterprise Group stock considered oversold (=20).
Growth Estimates Quarters
For the next quarter, the company expects to grow by 7.1% and 13.3% respectively.
More news about Public Service Enterprise Group.
28. Stryker Corp (SYK)
Shares of Stryker Corp rose by a staggering 11.68% in from $213.19 to $238.09 at 18:21 EST on Monday, after five consecutive sessions in a row of gains. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
Stryker Corporation is a company that specializes in medical technology. Two segments of the company are MedSurg, Neurotechnology and Orthopaedics & Spine. Orthopaedics and Spine provides implant products for hip and knee replacements as well as trauma and extremities surgery. The segment offers products for spinal injuries, deformities, and other degenerative treatments. MedSurg & Neurotechnology offers medical and surgical navigation equipment, surgical communication systems, patient handing, intensive care disposables, medical and emergency equipment, as well as reprocessed, remanufactured, medical device products for various specialties. The segment also offers neurotechnology products. These include products that can be used to perform minimally invasive procedures, products for open and brain-based surgery, orthobiologic products and biosurgery, like synthetic bone grafts, vertebral enhancement products and vertebral grafts; minimally invasive treatments for acute ischemic stroke and hemorhagic stroke, and craniomaxillofacial implants, including chest, maxillofacial and cranial wall devices as well as well as sealants and dural substitutes It sells products to hospitals and doctors through its subsidiaries and branches. Third-party distributors and dealers are also available in around 75 countries. Stryker Corporation was established in Kalamazoo in Michigan in 1941.
Annual Top and Bottom Value
Stryker Corp stock was valued at $238.09 as of 18:32 EST. This is way lower than its 52 week high of $280.43, and much higher than its 52-week low at $188.84.
Moving Average
Stryker Corp’s worth is way higher than its 50-day moving average of $215.99 and above its 200-day moving average of $228.43.
Volatility
Stryker Corp’s last week, last month’s, and last quarter’s current intraday variation average was 1.71%, 0.69%, and 1.70%.
Stryker Corp’s highest amplitude of average volatility was 1.72% (last week), 1.66% (last month), and 1.70% (last quarter).
More news about Stryker Corp.
29. Celanese (CE)
Shares of Celanese rose by a staggering 17.91% in from $92.01 to $108.49 at 18:21 EST on Monday, after four successive sessions in a row of gains. NYSE is dropping 1.85% to $15,474.79, following the last session’s upward trend.
Celanese Corporation, a technology and specialty materials company, manufactures and sells high performance engineered polymers in the United States and internationally. The company operates through three segments: Engineered Materials, Acetate Tow, and Acetyl Chain. The Engineered Materials segment develops, produces, and supplies specialty polymers for automotive and medical applications, as well as for use in industrial products and consumer electronics. It also offers acesulfame potassium, a sweetener for use in various beverages, confections, and dairy products; and food protection ingredients, such as potassium sorbate and sorbic acid for use in foods, beverages, and personal care products. The Acetate Tow segment provides acetate tows and flakes for use in filter products applications. The Acetyl Chain segment produces and supplies acetyl products, including acetic acid, vinyl acetate monomers, acetic anhydride, and acetate esters that are used as starting materials for colorants, paints, adhesives, coatings, and pharmaceuticals; and organic solvents and intermediates for pharmaceutical, agricultural, and chemical products. It also offers vinyl acetate-based emulsions for use in paints and coatings, adhesives, construction, glass fiber, textiles, and paper applications; and ethylene vinyl acetate resins and compounds, as well as low-density polyethylene for use in flexible packaging films, lamination film products, hot melt adhesives, automotive parts, and carpeting applications. In addition, it manufactures ultra-high molecular weight polyethylene. Celanese Corporation was founded in 1918 and is headquartered in Irving, Texas.
Moving Average
Celanese’s market value is much higher than its moving average over 50 days of $96.50, and far below its moving average over 200 days of $122.30.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Celanese’s stock is considered to be oversold (<=20).
Revenue growth
The year-on-year revenue growth was 13.1%. It now stands at 9.56 billion for the 12 trailing months.
Annual Top and Bottom Value
At 18:33 EST Celanese stock was valued at $108.49, which is way lower than the 52-week high at $176.50 but much higher than the 52-week low at $86.71.
More news about Celanese.
30. Zoom (ZM)
Shares of Zoom dropped by a staggering 10.21% in from $80.96 to $72.69 at 18:21 EST on Monday, after two successive sessions in a row of losses. NASDAQ is falling 1.93% to $11,239.94, following the last session’s downward trend.
Zoom Video Communications, Inc. provides unified communications platform in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. The company offers Zoom Meetings that offers HD video, voice, chat, and content sharing through mobile devices, desktops, laptops, telephones, and conference room systems; Zoom Phone, an enterprise cloud phone system; and Zoom Chat enables users to share messages, images, audio files, and content in desktop, laptop, tablet, and mobile devices. It also provides Zoom Rooms, a software-based conference room system; Zoom Hardware-as-a-Service allows users to access video communication technology from third party equipment; Zoom Conference Room Connector, a gateway for SIP/H.323 endpoints to join Zoom meetings; Zoom Events, which enables users to manage and host internal and external virtual events; OnZoom, a prosumer-focused virtual event platform and marketplace for Zoom users to create, host, and monetize online events; and Zoom Webinars to provide video presentations to large audiences from many devices. In addition, the company offers Zoom Developer Platform that enables developers, platform integrators, service providers, and customers to build apps and integrations using Zoom's video-based communications solutions, as well as integrate Zoom's technology into their products and services; Zoom App Marketplace, which helps developers to publish their apps, as well as third-party integrations of Zoom; and Zoom Contact Center, an omnichannel contact center solution. It serves individuals; and education, entertainment/media, enterprise infrastructure, finance, government, healthcare, manufacturing, non-profit/not for profit and social impact, retail/consumer products, and software/Internet industries. The company was formerly known as Zoom Communications, Inc. and changed its name to Zoom Video Communications, Inc. in May 2012. The company was incorporated in 2011 and is headquartered in San Jose, California.
Moving Average
Zoom’s value is lower than its 50-day average moving average $78.50, and much less than its 200-day average $104.13.
Growth Estimates Quarters
For the current quarter, the company expects to grow by a negative 31.6%, and negative 18.9% respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 4.22B for the twelve trailing months.
Annual Top and Bottom Value
Zoom stock was valued at $72.69 as of 18:33 EST at $268.88, which is below its 52 week high of $268.88 but above its 52 week low of $70.43.
More news about Zoom.
31. White Mountains Insurance Group (WTM)
Shares of White Mountains Insurance Group slid 1.54% in from $1324.26 to $1,303.87 at 18:21 EST on Monday, after two consecutive sessions in a row of losses. NYSE is sliding 1.85% to $15,474.79, following the last session’s upward trend.
White Mountains Insurance Group, Ltd., and its affiliates, provide insurance and financial services throughout the United States. Five segments make up the company: HG Global/BAM (arch), NSM, Kudu and Other Operations. The HG Global/BAM Segment provides insurance for municipal bonds that are issued to fund public purposes such as transportation, schools and utilities. It also offers reinsurance protection services. The Ark segment is responsible for writing a range of reinsurance products and insurance. This includes property, marine, energy, accident, health, casualty and specialty products. NSM serves as the managing general agent for special property and casualty insurance. It covers a variety of sectors including specialty transport, real estate and social services. Kudu provides capital solutions for boutique asset managers, including management buyouts, acquisitions, growth finance, legacy partner liquidity and generational ownership transfer. Other Operations offers travel insurance through a broker channel or direct to consumers. It manages separate accounts as well as pooled investments vehicles and pools for the insurance-linked sectors. This includes catastrophe bonds, collateralized insurance investments and industry losses warranties. White Mountains Insurance Group, Ltd., was established in 1980. It is located in Hamilton, Bermuda.
Yearly Top and Bottom Value
White Mountains Insurance Group’s stock is valued at $1,303.87 at 18:34 EST, below its 52-week high of $1,393.48 and way higher than its 52-week low of $978.51.
Volatility
White Mountains Insurance Group’s intraday variation average for the week and quarter ended last week was negative 1.56%, negative 0.05% and positive 1.42%.
White Mountains Insurance Group had the highest average volatility amplitudes of 1.78%, 1.41% and 1.42% in last week.
More news about White Mountains Insurance Group.